Details for New Drug Application (NDA): 208073

✉ Email this page to a colleague

NDA 208073 describes XIIDRA, which is a drug marketed by Bausch And Lomb Inc and is included in one NDA. It is available from two suppliers. There are sixteen patents protecting this drug. Additional details are available on the XIIDRA profile page.

The generic ingredient in XIIDRA is lifitegrast. Three suppliers are listed for this compound. Additional details are available on the lifitegrast profile page.

Summary for 208073

Tradename:	XIIDRA
Applicant:	Bausch And Lomb Inc
Ingredient:	lifitegrast
Patents:	16

Pharmacology for NDA: 208073

Mechanism of Action	Lymphocyte Function-Associated Antigen-1 Antagonists

Suppliers and Packaging for NDA: 208073

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073	NDA	Novartis Pharmaceuticals Corporation	0078-0911	0078-0911-12	12 POUCH in 1 CARTON (0078-0911-12) / 5 AMPULE in 1 POUCH (0078-0911-05) / .2 mL in 1 AMPULE
XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073	NDA	Novartis Pharmaceuticals Corporation	0078-0911	0078-0911-94	4 POUCH in 1 CARTON (0078-0911-94) / 5 AMPULE in 1 POUCH (0078-0911-95) / .2 mL in 1 AMPULE

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SOLUTION/DROPS;OPHTHALMIC			Strength	5%
Approval Date:	Jul 11, 2016	TE:	AB	RLD:	Yes
Patent:	10,124,000	Patent Expiration:	Nov 5, 2024	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
Patent:	11,058,677	Patent Expiration:	Dec 18, 2033	Product Flag?	Y	Substance Flag?		Delist Request?
Patent:	7,314,938	Patent Expiration:	Mar 10, 2025	Product Flag?	Y	Substance Flag?	Y	Delist Request?

Expired US Patents for NDA 208073

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016	10,124,000	⤷ Subscribe
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016	9,216,174	⤷ Subscribe
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016	7,928,122	⤷ Subscribe
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016	7,745,460	⤷ Subscribe
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016	7,790,743	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.